CQVA149A3401 Open Label Study of NVA237 or QVA149 in moderate COPD

• Research type

  Research Study

• Full title

  A prospective, multicentre, 12-week, randomised open-label study to evaluate the efficacy and safety of glycopyrronium (50 micrograms od) or indacaterol maleate and glycopyrronium bromide fixed-dose combination (110/50 micrograms od) regarding symptoms and health status in patients with moderate chronic obstructive pulmonary disease (COPD) switching from treatment with any standard COPD regimen.

• IRAS ID

  138102

• Contact name

  F Jaafar

• Contact email

  jeff@starduster.wanadoo.co.uk

• Sponsor organisation

  Novartis Pharma Services AG

• Eudract number

  2013-003127-11

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• REC name

  East Midlands - Nottingham 2 Research Ethics Committee

• REC reference

  14/EM/0077

• Date of REC Opinion

  25 Mar 2014

• REC opinion

  Further Information Favourable Opinion